A Phase 2, Open-label, Translational Biology Study of Momelotinib in Transfusion-Dependent Subjects With Primary Myelofibrosis (PMF) or Post-polycythemia Vera or Post-essential Thrombocythemia Myelofibrosis (Post-PV/ET MF)
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 08 Aug 2017
At a glance
- Drugs Momelotinib (Primary)
- Indications Essential thrombocythaemia; Myelofibrosis; Polycythaemia vera
- Focus Therapeutic Use
- Sponsors Gilead Sciences
- 16 Feb 2017 Status changed from recruiting to active, no longer recruiting.
- 29 Aug 2016 Planned End Date changed from 1 May 2017 to 1 Aug 2017.
- 29 Aug 2016 Planned primary completion date changed from 1 May 2017 to 1 Aug 2017.